Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research

Overview Zen Score Price Valuation Financials Forecast

Earnings & Revenue Dividends Ownership Technicals

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
FONR	FONAR CORP	$109.45M	$16.31	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ICLR	ICON PLC	$25.55B	$309.02	$344.38	11.44%	Strong Buy	8	6.04%	31.77%	N/A	N/A
STRR	STAR EQUITY HOLDINGS INC	$14.26M	$0.90	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVTY	REVVITY INC	$12.43B	$100.61	$118.89	18.17%	Buy	9	4.45%	21.89%	N/A	N/A
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$11.99B	$233.47	$264.00	13.08%	Buy	7	4.97%	47.49%	N/A	N/A
NEOG	NEOGEN CORP	$2.60B	$12.02	$17.00	41.43%	Hold	1	0.76%	526.68%	6.20%	4.25%
IDXX	IDEXX LABORATORIES INC	$39.69B	$480.60	$593.75	23.54%	Strong Buy	4	8.72%	7.44%	N/A	N/A
TMO	THERMO FISHER SCIENTIFIC INC	$218.49B	$572.38	$621.09	8.51%	Strong Buy	11	4.13%	56.87%	N/A	N/A
A	AGILENT TECHNOLOGIES INC	$40.87B	$139.45	$139.67	0.16%	Buy	12	3.35%	35.95%	N/A	N/A
ENZ	ENZO BIOCHEM INC	$53.27M	$1.04	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QGEN	QIAGEN NV	$9.62B	$42.98	$50.66	17.88%	Buy	5	5.09%	26.17%	N/A	N/A
DGX	QUEST DIAGNOSTICS INC	$15.26B	$137.38	$147.90	7.66%	Buy	10	2.82%	14.83%	N/A	N/A
SHC	SOTERA HEALTH CO	$3.12B	$11.02	$16.38	48.59%	Strong Buy	4	1.95%	547.37%	N/A	N/A
DHR	DANAHER CORP	$183.97B	$248.38	$278.30	12.05%	Strong Buy	10	7.40%	57.06%	N/A	N/A
MEDP	MEDPACE HOLDINGS INC	$12.16B	$392.57	$448.60	14.27%	Strong Buy	5	12.68%	0.10%	N/A	N/A
LH	LABORATORY CORP OF AMERICA HOLDINGS	$16.97B	$201.32	$245.50	21.95%	Buy	6	5.12%	113.65%	N/A	N/A
FLGT	FULGENT GENETICS INC	$643.37M	$21.50	$30.00	39.53%	Hold	2	5.61%	N/A	N/A	N/A
WAT	WATERS CORP	$19.02B	$321.25	$300.83	-6.36%	Hold	6	3.45%	29.72%	N/A	N/A
MTD	METTLER TOLEDO INTERNATIONAL INC	$26.89B	$1,251.95	$1.18k	-6.15%	Hold	5	3.63%	29.61%	N/A	N/A
SERA	SERA PROGNOSTICS INC	$351.82M	$10.85	N/A	N/A	N/A	N/A	47.06%	N/A	N/A	N/A
CSTL	CASTLE BIOSCIENCES INC	$671.68M	$24.33	$31.00	27.41%	Strong Buy	4	-5.28%	N/A	N/A	N/A
PRE	PRENETICS GLOBAL LTD	$63.83M	$5.23	$9.00	72.08%	Strong Buy	1	N/A	N/A	N/A	N/A
IQV	IQVIA HOLDINGS INC	$40.70B	$223.37	$265.67	18.94%	Strong Buy	9	5.86%	30.00%	N/A	N/A
PSNL	PERSONALIS INC	$77.78M	$1.54	$3.75	143.51%	Strong Buy	2	22.09%	N/A	N/A	N/A
NTRA	NATERA INC	$11.71B	$96.98	$90.83	-6.34%	Strong Buy	12	22.47%	N/A	N/A	N/A
PRPO	PRECIPIO INC	$8.30M	$5.80	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OLK	OLINK HOLDING AB (PUBL)	$2.86B	$23.01	$26.00	12.99%	Hold	2	24.72%	N/A	N/A	N/A
DRIO	DARIOHEALTH CORP	$46.22M	$1.57	$4.00	154.78%	Strong Buy	1	34.89%	N/A	N/A	N/A
ACRS	ACLARIS THERAPEUTICS INC	$96.46M	$1.36	$5.00	267.65%	Buy	2	-29.88%	N/A	N/A	N/A
STIM	NEURONETICS INC	$113.37M	$3.81	$8.00	109.97%	Strong Buy	1	10.95%	N/A	N/A	N/A
TWST	TWIST BIOSCIENCE CORP	$2.40B	$41.21	$44.60	8.23%	Strong Buy	5	12.78%	N/A	N/A	N/A
NEO	NEOGENOMICS INC	$1.95B	$15.30	$20.00	30.72%	Strong Buy	8	8.78%	N/A	N/A	N/A
DMTK	DERMTECH INC	$21.78M	$0.63	$1.38	118.92%	Buy	3	29.45%	N/A	-105.97%	-49.69%
EXAS	EXACT SCIENCES CORP	$11.27B	$62.07	$92.75	49.43%	Strong Buy	4	13.49%	N/A	N/A	N/A
OCX	ONCOCYTE CORP	$22.01M	$2.66	$4.06	52.74%	Buy	4	N/A	N/A	113.17%	30.93%
RDNT	RADNET INC	$3.51B	$51.20	$53.67	4.82%	Strong Buy	3	8.05%	960.00%	N/A	N/A
BNR	BURNING ROCK BIOTECH LTD	$82.67M	$0.81	N/A	N/A	N/A	N/A	N/A	N/A	-73.25%	-54.12%
BGLC	BIONEXUS GENE LAB CORP	$10.67M	$0.60	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APDN	APPLIED DNA SCIENCES INC	$3.18M	$3.75	$40.00	966.67%	Buy	1	4.14%	N/A	N/A	N/A
LAB	STANDARD BIOTOOLS INC	$728.20M	$2.51	$3.38	34.46%	Strong Buy	2	35.69%	N/A	N/A	N/A
GH	GUARDANT HEALTH INC	$2.30B	$18.88	$34.00	80.08%	Strong Buy	7	21.15%	N/A	N/A	N/A
XWEL	XWELL INC	$7.49M	$1.79	$7.00	291.06%	Buy	1	N/A	N/A	N/A	N/A
XGN	EXAGEN INC	$24.13M	$1.40	N/A	N/A	N/A	N/A	3.33%	N/A	N/A	N/A
BDSX	BIODESIX INC	$135.72M	$1.40	$3.50	150.00%	Strong Buy	1	32.42%	N/A	N/A	N/A
CDNA	CAREDX INC	$503.29M	$9.72	$15.00	54.32%	Strong Buy	2	-4.75%	N/A	N/A	N/A
ME	23ANDME HOLDING CO	$242.42M	$0.50	$0.47	-6.37%	Hold	1	6.26%	N/A	N/A	N/A
CHEK	CHECK-CAP LTD	$12.87M	$2.20	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ULS	UL SOLUTIONS INC	N/A	$35.40	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRPH	PROPHASE LABS INC	$97.81M	$5.42	$11.00	102.95%	Buy	1	65.50%	N/A	N/A	N/A
AWH	ASPIRA WOMEN's HEALTH INC	$39.62M	$3.21	$3.30	2.80%	Hold	1	16.89%	N/A	N/A	N/A
NDRA	ENDRA LIFE SCIENCES INC	$3.61M	$0.33	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPK	OPKO HEALTH INC	$906.09M	$1.30	$3.17	143.62%	Strong Buy	3	0.94%	N/A	N/A	N/A
NOTV	INOTIV INC	$110.13M	$4.27	$18.25	327.40%	Strong Buy	2	-1.09%	N/A	N/A	N/A
VNRX	VOLITIONRX LTD	$73.12M	$0.89	$3.50	292.82%	Strong Buy	2	N/A	N/A	N/A	N/A
MDXH	MDXHEALTH SA	$8.57M	$3.14	$7.50	138.85%	Strong Buy	2	11.69%	N/A	N/A	N/A
GENE	GENETIC TECHNOLOGIES LTD	$520.53k	$2.26	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MYGN	MYRIAD GENETICS INC	$1.75B	$19.47	$22.00	12.99%	Buy	4	8.80%	N/A	N/A	N/A
ISPC	ISPECIMEN INC	$2.39M	$0.26	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIAF	BIOAFFINITY TECHNOLOGIES INC	$24.07M	$2.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ILMN	ILLUMINA INC	$18.79B	$117.93	$148.44	25.87%	Buy	9	4.80%	N/A	N/A	N/A
PMD	PSYCHEMEDICS CORP	$14.64M	$2.55	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRIB	TRINITY BIOTECH PLC	$13.81M	$1.80	N/A	N/A	N/A	N/A	17.89%	N/A	N/A	N/A
MYNZ	MAINZ BIOMED NV	$15.60M	$0.74	$3.00	307.06%	Buy	1	N/A	N/A	N/A	N/A
MMA	ALTA GLOBAL GROUP LTD	N/A	$3.55	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNTG	CENTOGENE NV	$12.22M	$0.44	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TTOO	T2 BIOSYSTEMS INC	$20.51M	$3.72	$3.00	-19.35%	Hold	1	N/A	N/A	N/A	N/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 3.69% over the past year, overperforming other diagnostic & research stocks by 4 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second best diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 66.35% over the past year, overperforming other diagnostic & research stocks by 67 percentage points.

Icon has an average 1 year price target of $344.38, an upside of 11.44% from Icon's current stock price of $309.02.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Icon, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the third best diagnostic & research stock with a Zen Score of 46, which is 19 points higher than the diagnostic & research industry average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 37.4% over the past year, overperforming other diagnostic & research stocks by 38 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 2.98%, which is 2 percentage points higher than the diagnostic & research industry average of 1.36%.

Qiagen Nv's dividend payout ratio of 87.2% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.1%, which is 1 percentage points higher than the diagnostic & research industry average of 1.36%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.2% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)

Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.43%, which is the same as the diagnostic & research industry average of 1.36%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 56.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.85% in the last day, and up 0.7% over the last week. Twist Bioscience was the among the top gainers in the diagnostics & research industry, gaining 28.74% yesterday.

Twist Bioscience shares are trading higher after the company reported better-than-expected Q2 financial results.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 52 points higher than the diagnostic & research industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 37.4% in the past year. It has overperformed other stocks in the diagnostic & research industry by 38 percentage points.

2. Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 52 points higher than the diagnostic & research industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -59.85% in the past year. It has underperformed other stocks in the diagnostic & research industry by -59 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 52 points higher than the diagnostic & research industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 3.69% in the past year. It has overperformed other stocks in the diagnostic & research industry by 4 percentage points.

Are diagnostic & research stocks a good buy now?

52.08% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 10.51% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 38.44x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.